Literature DB >> 2964856

The microbial colonization of inflamed acne vulgaris lesions.

J P Leeming1, K T Holland, W J Cuncliffe.   

Abstract

Seventy one papules in the early stages of inflammatory development were isolated from acne vulgaris affected skin and their content of micro-organisms characterized. The progress of lesions prior to excision was monitored by tracing an area of the upper back onto a transparent acetate sheet. This template was used the next day, and in some cases after 3 days, to identify inflamed lesions of less than 1 day and 2-3 days duration. These were biopsied, and pilosebaceous units isolated by micro-dissection, homogenized and microbial populations studied by viable counting and microscopy. Propionibacteria colonised 68% of '1 day' duration lesions and 79% of '3 day' duration lesions; staphylococci colonized 19% and 32% respectively and Pityrosporum spp. (Malassezia furfur) were found in 52% and 68%. Although the prevalence of each microbial group was higher in the more chronic lesions, these differences were not statistically significant. The microbial profile of inflamed lesions was similar both qualitatively and quantitatively to non-inflamed lesions studied previously. These results call into question the role of micro-organisms as the initiators of inflammation in acne vulgaris.

Entities:  

Mesh:

Year:  1988        PMID: 2964856     DOI: 10.1111/j.1365-2133.1988.tb01775.x

Source DB:  PubMed          Journal:  Br J Dermatol        ISSN: 0007-0963            Impact factor:   9.302


  26 in total

1.  Comparative activity of the topical quinolone OPC-7251 against bacteria associated with acne vulgaris.

Authors:  K Vogt; J Hermann; U Blume; H Gollnick; H Hahn; U F Haustein; C E Orfanos
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1992-10       Impact factor: 3.267

Review 2.  Dermatology.

Authors:  M H Rustin
Journal:  Postgrad Med J       Date:  1990-11       Impact factor: 2.401

3.  Antimicrobial evaluation of nadifloxacin (OPC-7251), a new topical quinolone, in acne vulgaris.

Authors:  K Vogt; H Hahn; J Hermann; U F Haustein; U Blume; H Gollnick; C E Orfanos
Journal:  Drugs       Date:  1995       Impact factor: 9.546

4.  IL-1β drives inflammatory responses to propionibacterium acnes in vitro and in vivo.

Authors:  Magdalena Kistowska; Samuel Gehrke; Dragana Jankovic; Katrin Kerl; Antonia Fettelschoss; Laurence Feldmeyer; Gabriele Fenini; Antonios Kolios; Alexander Navarini; Ruta Ganceviciene; Jürgen Schauber; Emmanuel Contassot; Lars E French
Journal:  J Invest Dermatol       Date:  2013-10-24       Impact factor: 8.551

Review 5.  Azelaic acid. A review of its pharmacological properties and therapeutic efficacy in acne and hyperpigmentary skin disorders.

Authors:  A Fitton; K L Goa
Journal:  Drugs       Date:  1991-05       Impact factor: 9.546

6.  Antimicrobial property of lauric acid against Propionibacterium acnes: its therapeutic potential for inflammatory acne vulgaris.

Authors:  Teruaki Nakatsuji; Mandy C Kao; Jia-You Fang; Christos C Zouboulis; Liangfang Zhang; Richard L Gallo; Chun-Ming Huang
Journal:  J Invest Dermatol       Date:  2009-04-23       Impact factor: 8.551

7.  New insights into acne pathogenesis: propionibacterium acnes activates the inflammasome.

Authors:  Emmanuel Contassot; Lars E French
Journal:  J Invest Dermatol       Date:  2014-02       Impact factor: 8.551

8.  IL-17: a key player in the P. acnes inflammatory cascade?

Authors:  Diane M Thiboutot; Alison M Layton; E Anne Eady
Journal:  J Invest Dermatol       Date:  2014-02       Impact factor: 8.551

Review 9.  The role of inflammation in the pathology of acne.

Authors:  Emil A Tanghetti
Journal:  J Clin Aesthet Dermatol       Date:  2013-09

10.  Antibodies elicited by inactivated propionibacterium acnes-based vaccines exert protective immunity and attenuate the IL-8 production in human sebocytes: relevance to therapy for acne vulgaris.

Authors:  Teruaki Nakatsuji; Yu-Tsueng Liu; Cheng-Po Huang; Christos C Zoubouis; Richard L Gallo; Chun-Ming Huang
Journal:  J Invest Dermatol       Date:  2008-05-08       Impact factor: 8.551

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.